Impact of inflammatory molecules on disease progression in advanced pancreatobiliary cancer
- Conditions
- pancreatic cancer, biliary tract cancer
- Registration Number
- JPRN-UMIN000005493
- Lead Sponsor
- Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
- Brief Summary
High IL-6 and IL-1b levels were poor prognostic factors for overall survival in a multivariate analysis (P = 0.011 and P = 0.048, respectively). Patients with both a high IL-6 level and a high IL-1b level exhibited shortened overall and progression-free survival, a reduction in the tumour control rate, and a high dose intensity of GEM compared with patients with low levels of both IL-6 and IL-1b.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 60
Not provided
1) History of treatment with corticosteroids(oral intake or intravenously) for chronic inflammatory disease, such as interstitial lung disease, collagen disease, and Crohn disease 2) Treatment with corticosteroids (oral intake or intravenously) for allergic disease within four weeks 3) Surgical treatment within four weeks 4) Paralytic or mechanical bowel obstruction 5) Simultaneous or metachronous double cancers 6) Any other patient whom the physician in charge of the study judges to be unsuitable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum level mRNA expression immunohistochemistry metabolome analysis phsopho-protein analysis cachexia body composition symptoms clinical data
- Secondary Outcome Measures
Name Time Method the distribution of KRAS mutation